Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.
Department of Transplantation, Mayo Clinic, Jacksonville, FL.
Liver Transpl. 2019 Sep;25(9):1363-1374. doi: 10.1002/lt.25589. Epub 2019 Jul 20.
The need for liver transplantation (LT) among older patients is increasing, but the role of LT in the elderly (≥70 years) is not well defined. We retrospectively reviewed all primary LTs from 1998 through 2016 at our center. Survival and associated risk factors were analyzed with Cox regression and Kaplan-Meier methods for LT recipients in 3 age groups: <60, 60-69, and ≥70 years. Among 2281 LT recipients, the median age was 56 years (range, 15-80 years), and 162 were aged ≥70 years. The estimated 5- and 10-year patient survival probabilities for elderly LT recipients were lower (70.8% and 43.6%) than for recipients aged 60-69 years (77.2% and 64.6%) and <60 years (80.7% and 67.6%). Patient and graft survival rates associated with LT improved over time from the pre-Model for End-Stage Liver Disease era to Share 15, pre-Share 35, and Share 35 for the cohort overall (P < 0.001), but rates remained relatively stable in septuagenarians throughout the study periods (all P > 0.45). There was no incremental negative effect of age at LT among elderly patients aged 70-75 years (log-rank P = 0.32). Among elderly LT recipients, greater requirement for packed red blood cells and longer warm ischemia times were significantly associated with decreased survival (P < 0.05). Survival of LT recipients, regardless of age, markedly surpassed that of patients who were denied LT, but it was persistently 20%-30% lower than the expected survival of the general US population (P < 0.001). With the aging of the population, select older patients with end-stage liver diseases can benefit from LT, which largely restores their expected life spans.
肝移植(LT)在老年患者中的需求正在增加,但老年人(≥70 岁)的 LT 作用尚未明确。我们回顾性分析了我们中心 1998 年至 2016 年所有的原发性 LT。通过 Cox 回归和 Kaplan-Meier 方法对 3 个年龄组的 LT 受者(<60、60-69 和≥70 岁)的生存率及相关危险因素进行分析。在 2281 例 LT 受者中,中位年龄为 56 岁(范围,15-80 岁),162 例年龄≥70 岁。老年 LT 受者的 5 年和 10 年患者生存率估计值(70.8%和 43.6%)低于 60-69 岁(77.2%和 64.6%)和<60 岁(80.7%和 67.6%)。从终末期肝病模型时代前到 Share 15、Share 35 前和总体 Share 35,LT 相关的患者和移植物存活率随时间的推移而提高(P<0.001),但在整个研究期间 70 多岁患者的存活率仍相对稳定(均 P>0.45)。在 70-75 岁的老年患者中,LT 年龄没有累积负面影响(对数秩 P=0.32)。在老年 LT 受者中,需要更多的浓缩红细胞和更长的热缺血时间与生存率降低显著相关(P<0.05)。LT 受者的生存率无论年龄大小,都明显超过了被拒绝 LT 的患者,但仍比美国一般人群的预期寿命低 20%-30%(P<0.001)。随着人口老龄化,选择少数患有终末期肝病的老年患者可以从 LT 中受益,这在很大程度上恢复了他们的预期寿命。